Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510542 | 0.95 | ALOX5 (0.53) | ALDH1A1CA12CA1CA2CA14 | |
| SCHEMBL9579736 | 0.93 | ALOX5 (0.51) | ALDH1A1CA12CA1CA2CA14 | |
| SCHEMBL670713 | 0.89 | CA12 (0.54) | ALDH1A1CA12CA1CA2CA14 | |
| Hydrochloric Acid SCHEMBL5820054 | 0.87 | ALDH1A1 (0.56) | ALDH1A1CA12CA1CA2CA14 | |
| SCHEMBL4774241 | 0.84 | AOC3 (0.56) | ALDH1A1SMN1; SMN2TSHRL3MBTL1KDM4E | |
| SCHEMBL13570066 | 0.84 | ALOX5 (0.60) | ALDH1A1CA12CA1CA2CA14 | |
| SCHEMBL80578 | 0.83 | TAAR1 (0.60) | ABCB1ALOX5PTGS2 | |
| SCHEMBL30118916 | 0.83 | TAAR1 (0.60) | ABCB1ALOX5PTGS2 | |
| SCHEMBL6172042 | 0.82 | ALOX5 (0.50) | ALDH1A1ALOX5PTGS2SMN1; SMN2KDM4E | |
| SCHEMBL11232865 | 0.82 | CA12 (0.51) | ALDH1A1CA12CA1CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| EP-2049556-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | Basilea Pharmaceutica AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | ALDH1A1 4616/4885CA12 3116/4885CA1 3957/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | ALDH1A1 3239/4885CA12 1479/4885CA1 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.